How to Help Your Patients Save Money on Incruse Ellipta: A Provider's Guide to Savings Programs

Cost is one of the most significant barriers to medication adherence in COPD — and Incruse Ellipta (umeclidinium 62.5 mcg) is no exception. At $350–$415 per 30-day inhaler without insurance, many patients face a difficult financial decision every month. As a prescriber, you are often the first line of defense against cost-related non-adherence. This guide gives you a complete picture of the savings programs available for Incruse Ellipta in 2026 and how to help your patients access them.

The Cost Landscape for Incruse Ellipta in 2026

Understanding the pricing environment is the first step in helping patients afford Incruse Ellipta. Key facts for 2026:

• No generic available. The earliest potential generic entry is December 2027 based on current patent protections. Until then, all patients must use the brand-name product.
• Retail price: $350–$415 per 30-day inhaler without insurance, depending on pharmacy.
• Insurance tier: Commercial plans may place Incruse Ellipta on Tier 3 or Tier 4, resulting in copays of $50–$150/month for patients without savings programs.
• Medicare Part D: Variable copays depending on plan tier. The 2025 Medicare Part D out-of-pocket cap of $2,000 provides protection for patients managing multiple chronic medications.

GSK "Pay No More Than $35" Savings Coupon

This is the most impactful savings program for commercially insured COPD patients. Effective January 1, 2025, GlaxoSmithKline capped out-of-pocket costs for Incruse Ellipta at $35 per prescription per month for eligible patients — for up to 12 fills per calendar year.

Who qualifies: Commercially insured patients and patients without insurance coverage.

Who does NOT qualify: Government-insured patients (Medicare Part D, Medicaid, TRICARE, VA). These patients are referred to the GSK For You program.

How to refer patients: Direct patients to gsksavings.com or have them ask the pharmacist at the point of sale. The savings card can also be printed from the GSK website. Toll-free: 888-825-5249.

Clinical note: This program covers up to 12 prescriptions per year. For patients who fill quarterly (90-day supplies via mail order), this works out to 4 fills — equivalent to 12 months of once-monthly fills. Verify coverage details with GSK as terms may change.

GSK For You Patient Assistance Program

For uninsured, underinsured, or Medicare patients who cannot afford Incruse Ellipta, the GSK For You Patient Assistance Program (PAP) can provide the medication at no cost. This is an income-based program administered by GSK.

Eligibility criteria (general): Income below a defined threshold (varies by program year), limited or no prescription coverage, U.S. residency, and a valid prescription from a licensed U.S. prescriber.

Provider role: Prescribers must complete and sign a portion of the application and attest to the patient's diagnosis and medical need. Applications are processed electronically or by phone.

Contact: 866-728-4368 or 866-316-7263. Visit gskforyou.com for enrollment details.

Prior Authorization Strategy: Getting Coverage Approved

Prior authorization (PA) may be required by commercial plans and some Medicare Part D plans for Incruse Ellipta. Successful PA reduces the patient's copay burden by moving the drug from a cash claim to a covered claim. Strategies for efficient PA:

• Document spirometry results confirming obstructive pattern (FEV1/FVC < 0.70 post-bronchodilator) and severity (GOLD classification).
• Document symptom burden using validated tools such as the COPD Assessment Test (CAT score ≥10) or mMRC dyspnea scale (≥2).
• Meet step therapy requirements by documenting trial of first-tier agents if required (typically ipratropium or short-acting bronchodilators). For patients who cannot tolerate these, document medical reasons.
• Appeal denied PAs promptly with a letter of medical necessity. Most appeals that include clinical documentation and rationale are successful. Peer-to-peer calls with the insurance medical director can resolve complex cases.

Formulary Alternatives: When to Consider Switching vs. Appealing

If a patient's plan doesn't cover Incruse Ellipta or places it on a very high tier, consider whether a formulary-preferred LAMA would serve them equally well. Tiotropium (Spiriva) is on more formularies at preferred tiers than Incruse Ellipta. For plans that cover Anoro Ellipta (LAMA + LABA) at a lower tier, stepping up may actually reduce the patient's total cost while improving bronchodilation.

For patients who are stable and well-controlled on Incruse Ellipta, consider appealing the coverage decision rather than switching. Stability is a strong clinical argument — disrupting a regimen that's working carries its own risk of exacerbation.

Helping Medicare Patients Manage Costs

Medicare patients cannot use the commercial GSK coupon, but they have other tools:

• $2,000 Part D annual out-of-pocket cap (as of 2025): Incruse Ellipta costs will count toward this cap. Patients who reach the $2,000 cap pay $0 for the rest of the year.
• Medicare Prescription Payment Plan: Starting in 2025, Medicare patients can spread out-of-pocket drug costs across the year rather than paying large amounts early in the plan year.
• Extra Help / Low Income Subsidy (LIS): Medicare patients with limited income may qualify for the Extra Help program, which significantly reduces Part D premiums and drug copays. Screen for eligibility and refer to Social Security Administration at ssa.gov.
• GSK For You PAP for Medicare patients: Income-qualified Medicare patients may still qualify for the GSK For You patient assistance program. Enrollment requires a prescriber signature.

Resources to Share With Patients

• GSK savings and assistance: gsksavings.com and gskforyou.com
• GoodRx (goodrx.com): Compare pharmacy prices; coupon reduces retail to ~$203.90
• Medicare Extra Help: ssa.gov/medicare/part-d-extra-help/
• NeedyMeds.org: Lists additional pharmaceutical assistance programs

Partnering With medfinder to Help Patients Access Their Medication

Cost is only one barrier — availability is another. Even with savings programs in place, patients still need to find a pharmacy that carries Incruse Ellipta. medfinder helps bridge the availability gap by contacting pharmacies near patients to check which ones can fill their prescription, then delivering results by text. When you combine GSK savings programs with medfinder's pharmacy access service, patients have both the cost reduction and the availability information they need to stay adherent. Visit medfinder.com/providers to learn how to recommend medfinder to your COPD patients.